Adjuvant chemotherapy with melatonin for targeting human cancers: A review
Autor: | Nasser Hashemi Goradel, Eniseh Salehi, Bagher Farhood, Maryam Shabani Nashtaei, Keywan Mortezaee, Neda Khanlarkhani, Masoud Najafi, Zeinab Namjoo |
---|---|
Rok vydání: | 2018 |
Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Combination therapy Cell Survival Physiology medicine.medical_treatment Clinical Biochemistry Apoptosis Targeted therapy Melatonin 03 medical and health sciences 0302 clinical medicine Neoplasms Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Adjuvant therapy Humans Chemotherapy business.industry Cancer Cell Biology medicine.disease Circadian Rhythm 030104 developmental biology Chemotherapy Adjuvant 030220 oncology & carcinogenesis Cancer cell Quality of Life business Hormone medicine.drug |
Zdroj: | Journal of Cellular Physiology. 234:2356-2372 |
ISSN: | 1097-4652 0021-9541 |
DOI: | 10.1002/jcp.27259 |
Popis: | Melatonin is a multifunctional hormone that has long been known for its antitumoral effects. An advantage of the application of melatonin in cancer therapy is its ability to differentially influence tumors from normal cells. In this review, the roles of melatonin adjuvant therapy in human cancer are discussed. Combination of melatonin with chemotherapy could provide synergistic antitumoral outcomes and resolve drug resistance in affected patients. This combination reduces the dosage for chemotherapeutic agents with the subsequent attenuation of side effects related to these drugs on normal cells around tumor and on healthy organs. The combination therapy increases the rate of survival and improves the quality of life in affected patients. Cancer cell viability is reduced after application of the combinational melatonin therapy. Melatonin does all these functions by adjusting the signals involved in cancer progression, re-establishing the dark/light circadian rhythm, and disrupting the redox system for cancer cells. To achieve effective therapeutic outcomes, melatonin concentration along with the time of incubation for this indoleamine needs to be adjusted. Importantly, a special focus is required to be made on choosing an appropriate chemotherapy agent for using in combination with melatonin. Because of different sensitivities of cancer cells for melatonin combination therapy, cancer-specific targeted therapy is also needed to be considered. For this review, the PubMed database was searched for relevant articles based on the quality of journals, the novelty of articles published by the journals, and the number of citations per year focusing only on human cancers. © 2018 Wiley Periodicals, Inc. |
Databáze: | OpenAIRE |
Externí odkaz: |